Introduction
Neuroblastomas are pediatric tumors of neuroendocrine origin with very diverse phenotypes ranging from spontaneously regressing tumors in infants to very aggressive malignancies, which account for approximately 15% of all childhood cancer deaths (Maris, 2005; Maris et al., 2007; Park et al., 2008) . These tumors develop from precursors of sympathetic neurons and express neuronal markers, such as the sympathetic neurotransmitter neuropeptide Y (NPY) and its receptors (Biedler et al., 1978; O'Hare and Schwartz, 1989a, b; Kitlinska et al., 2005) . NPY, acting through multiple G-protein-coupled receptors (Y1-Y5), is a growth factor for a variety of cells, such as neuronal precursors, vascular smooth muscle and endothelial cells (Zukowska-Grojec et al., 1993 Hansel et al., 2001; Pons et al., 2003 Pons et al., , 2008 Movafagh et al., 2006) . The peptide has also been shown to stimulate angiogenesis in a variety of physiological and pathological conditions (Kitlinska et al., 2002; Yoon et al., 2002; Ekstrand et al., 2003; Lee et al., 2003b; Koulu et al., 2004) .
Owing to their sympathetic origin, neuroblastomas release high levels of NPY, which often results in increased peptide concentrations in a patient's plasma. These elevated plasma NPY levels are associated with poor clinical outcome of the disease in children over 1 year of age, with advanced stage neuroblastomas (Cohen et al., 1990; Kogner et al., 1994; Dotsch et al., 1998) . These data correlate with our previous findings that exogenous NPY enhances neuroblastoma growth by two processes, a direct autocrine stimulation of tumor cell proliferation and a paracrine angiogenic effect (Kitlinska et al., 2005) . Both processes are mediated mainly by Y2 receptors (Y2Rs), with some contribution from Y5R. As Y2R is the main angiogenic receptor in the NPY system (Ekstrand et al., 2003; Lee et al., 2003a; Koulu et al., 2004) and the most commonly expressed NPY receptor in neuroblastoma cells (Korner et al., 2004; Kitlinska et al., 2005) , we focused on assessing Y2Rs as potential therapeutic targets. We sought to determine whether blocking actions of endogenous NPY by targeting Y2R will be sufficient to inhibit neuroblastoma growth. We show that Y2R blockage in neuroblastoma cells leads to decreased p44/42 mitogen-activated protein kinase (MAPK) activation, which results in a reduced proliferation rate, as well as increased Bim levels and enhanced apoptosis. Moreover, blocking the Y2R pathway impairs tumor vascularization, which, together with the direct effect on neuroblastoma cells, leads to significant inhibition of tumor growth in vivo.
Results
NPY is an autocrine growth factor for neuroblastomas Our previous data indicated that exogenous NPY stimulates proliferation of SK-N-BE(2) neuroblastoma cells (Kitlinska et al., 2005) . In this study, high NPY mRNA levels were detected by real-time reverse transcription-polymerase chain reaction (RT-PCR) in eight neuroblastoma cell lines and release of the peptide was confirmed by enzyme-linked immunosorbent assay (ELISA) on their corresponding culture media ( Figure 1a ). To determine whether blocking endogenous NPY will be sufficient to inhibit neuroblastoma growth, SK-N-BE(2) cells were transfected with two different NPY small interfering RNAs (siRNAs). Both siRNAs decreased NPY mRNA levels by approximately 80%, as measured by real-time RT-PCR, which resulted in approximately 70% decreased NPY concentration in the culture media ( Figure 1b ). These decreases in NPY levels led to a reduction in SK-N-BE(2) cell growth measured by conversion of tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; MTS) to formazan product (MTS assay) ( Figure 1b ). The growth inhibition caused by NPY siRNA was rescued by exogenous NPY (10 À7 M). In line with this, in three other neuroblastoma cell lines, NPY siRNA had growth-inhibitory effects comparable with that observed in SK-N-BE(2) cells ( Figure 1c ).
Blocking Y2R prevents actions of endogenous NPY and inhibits neuroblastoma growth in vitro Like NPY, Y2R was commonly expressed in various neuroblastoma cells (Figure 2a ). To determine whether a reduction in Y2R levels prevents the growth-promoting effect of endogenous NPY, SK-N-BE(2) cells were transfected with two different Y2R siRNAs. The Y2R knockdown (approximately 70% reduction in mRNA and 40-50% decrease in protein levels) resulted in statistically significant decreases in SK-N-BE(2) cell growth ( Figure 2b) . In contrast to the effect with NPY siRNA, growth inhibition induced by Y2R siRNA was not rescued by exogenous NPY (Figure 2b ). To increase the efficiency of blocking the NPY system, the most effective NPY and Y2R siRNAs were co-transfected into SK-N-BE(2) cells. The resulting growth inhibition (approximately 60%) was significantly greater than that observed with single siRNAs (Figure 2b ), indicating that efficient blockage of the NPY system exerts a strong inhibitory effect on neuroblastoma cell growth.
The effect of Y2R blockage on neuroblastoma cell growth was also tested in six other cell lines. Forty-eight hours treatment with Y2R antagonist at a concentration of 10 À6 M (dose based on previous studies; Kitlinska et al., 2005) resulted in modest, but statistically significant growth-inhibitory effects in all tested cell lines (Figure 2c ). This was further confirmed by the growth-inhibitory effect of Y2R siRNA in three selected cell lines.
Y2R antagonist inhibits growth of neuroblastoma cells by decreasing endogenous proliferation and inducing apoptosis
To determine a mechanism of the growth-inhibitory effect resulting from Y2R blockade in neuroblastoma, SK-N-BE(2) cells were treated with Y2R antagonist (10 À8 -10 À5 M) and assayed for levels of proliferation and apoptosis. The treatment resulted in a dosedependent inhibition of cell growth measured by MTS assay, which was associated with a decreased percent of bromodeoxyuridine (BrdU)-positive cells ( Figure 3a ). These data indicate that Y2R antagonist acts by inhibiting neuroblastoma cell proliferation induced by endogenous NPY. Simultaneously, however, an increase in apoptosis measured by caspase 3/7 activity was also observed (Figure 3a ). This mechanism was further confirmed in SK-N-AS cells treated with NPY and Y2R siRNAs. Interestingly, although both types of siRNA induced comparable growth-inhibitory effects (MTS assay), increased apoptosis was the main mechanism of NPY siRNA actions, while decreased proliferation prevailed in the Y2R siRNA-transfected cells ( Figure 3d ). However, the same Y2R siRNA caused a 28% increase in apoptosis in SK-N-BE(2) cells (data not shown).
The growth-inhibitory effect of Y2R antagonist is mediated by a decrease in p44/42 MAPK activation and an upregulation of Bim Previously, we have shown that exogenous NPY stimulates neuroblastoma proliferation by activation of the p44/42 MAPK pathway and that this effect can be blocked by Y2R antagonist (Kitlinska et al., 2005) .
To determine whether disruption of endogenous NPY stimulation by Y2R blockage affects basal p44/42 MAPK activity, SK-N-BE(2) cells were treated with Y2R antagonist at concentrations ranging from 10 À8 to 10 À6 M for 6, 12 and 24 h. After 12 h, a significant, dosedependent decrease in phospho-p44/42 MAPK levels was observed (Figure 3b ), supporting the antiproliferative actions of Y2R antagonist. In contrast, no significant changes in Akt activation were detected. After 24 h treatment, the decrease in MAPK activation was followed by an increase in levels of Bim (Figure 3c ), a proapoptotic protein known to be regulated by p44/42 MAPK. This change was observed for all three known isoforms of Bim: BimEL, BimL and BimS. The Y2R antagonist-induced increase in Bim protein levels was mimicked by an inhibitor of p44/42 MAPK pathway, PD098059. Treatment with this inhibitor resulted in a change in BimEL gel migration, with only one detectable band corresponding to its non-phosphorylated form (Ley et al., 2003) . Similarly, increased relative intensity of the lower, non-phosphorylated BimEL band was observed in Y2R antagonist-treated samples (Figure 3c ). p44/42 MAPK-mediated phosphorylation of Bad, which can also contribute to the antiapoptotic effects of this MAPK, was not detected. Also, no In SK-N-BE(2) cells, NPY siRNA inhibited expression of the peptide (real-time RT-PCR) and its release into the cell culture media (ELISA), which resulted in a decreased number of viable cells (MTS assay). The growth-inhibitory effect of NPY siRNA was rescued by exogenous NPY (10 À7 M). NC, negative control siRNA; NPY-1 and NPY-2, two different siRNAs for NPY. (c) In three selected cell lines, NPY siRNA exerted growth-inhibitory effects comparable to that observed in SK-N-BE(2) cells.
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C Lu et al In SK-N-BE(2) cells, Y2R antagonist at concentrations ranging from 10 À8 to 10 À5 M decreased the number of viable cells (MTS assay) and proliferation rate (BrdU uptake), as well as increased apoptosis (caspase 3/7 activity). The measurements were performed 48, 12 and 24 h after treatment, respectively. (b) In SK-N-BE(2) cells treated as above, 12 h after treatment, Y2R antagonist dose-dependently decreased the levels of phosphorylated p44/42 MAPK (western blot). No significant differences in phosphorylated Akt were observed. (c) At 24 h after treatment, the reduction in p44/42 MAPK was followed by an increase in protein levels of three isoforms of Bim (western blot followed by densitometry). The level of BimEL phosphorylation decreased with treatment, as measured by the ratio of non-phosphorylated (lower band) to phosphorylated (upper band) form of Bim EL (N-P/P BimL). This effect was mimicked by MAPK kinase 1 inhibitor, PD98059 (5 Â 10 À5 M). No changes in Bcl-X L were observed. (d) In SK-N-AS cells, transfection with NPY siRNA or Y2R siRNA decreased the number of viable cells (72 h, MTS assay) and the levels of active p44/42 MAPK (western blot). In NPY siRNA-treated cells, these changes were associated with increased caspase 3/7 activity and upregulation of Bim (western blot), whereas in Y2R siRNA-transfected cells, the proliferation level was reduced (EdU uptake). The same Y2R siRNA upregulated Bim in SK-N-BE(2) cells. NC, negative control siRNA.
difference in levels of Bcl-X L , a prosurvival protein implicated in the regulation of neuronal cell death, was observed ( Figure 3c ). These results were corroborated by a decrease in the endogenous levels of activated p44/42 MAPK observed in SK-N-AS cells transfected with NPY and Y2R siRNAs (Figure 3d ). Moreover, in NPY siRNA-treated SK-N-AS cells and Y2R siRNAtreated SK-N-BE(2) cells, a significant increase in apoptosis was associated with elevated levels of Bim (Figure 3d ).
Y2R antagonist inhibits growth of neuroblastoma xenografts
To validate our findings in vivo, Y2R antagonist was tested in a neuroblastoma xenograft model. SK-N-BE(2) cells were injected subcutaneously into nude mice and treated with daily local injections of Y2R antagonist (10 À6 M). In the first experiment, the treatment started 1 day after tumor cell inoculation and lasted for 6 weeks (Figure 4b ). At 33 days after initiation of treatment, the median of tumor growth was significantly higher for the control group (606.5 mm 3 ) than for the Y2R antagonist group (53.2 mm 3 ).
In the second experiment, the treatment started 14 days after tumor cell inoculation, when increases in tumor size were first observed. Nine days following initial treatment, the median tumor growth was 516.3 mm 3 for the control group and 44.2 mm 3 for the Y2R antagonist group (Figure 4b) . A similar growthinhibitory effect was observed in SK-N-AS xenografts treated in the same way ( Figure 4b ).
Y2R antagonist decreases proliferation rate and increases apoptosis in neuroblastoma xenografts in vivo
To determine the mechanisms by which Y2R antagonist inhibits neuroblastoma growth in vivo, SK-N-BE(2) tumors were stained for markers of proliferation (Ki67) and apoptosis (TdT-mediated dUTP nick end labeling; TUNEL). The proliferation levels were significantly lower in Y2R antagonist-treated tumors, as compared with the controls (Figure 4c ). This effect was also associated with a significant increase in apoptosis levels (Figure 4c ). Consistent with these results and our findings in vitro, the levels of activated p44/42 MAPK in Y2R antagonist-treated tumors were significantly decreased, as compared with the controls (Figure 4d ). However, no evident differences in Bim levels were observed (data not shown).
Y2R antagonist reduces the angiogenic potential of neuroblastomas Our previous data indicated that NPY released from neuroblastomas promotes tumor vascularization (Kitlinska et al., 2005) . To determine whether this effect is mediated by Y2R, we assessed human dermal microvascular endothelial cell (HMVEC) expression levels for this receptor. Although not detectable under basal conditions, Y2R mRNA was induced by hypoxia (0.1% oxygen for 24 h) and NPY (10 À7 M for 6 h) treatment (Figure 5a ). Moreover, in HMVECs, Y2R antagonist (10 À6 M) completely blocked the proliferative effect of NPY (10 À8 M, optimal dose based on previous studies; Kitlinska et al., 2002) and significantly reduced proliferation induced by SK-N-BE(2)-conditioned media (Figure 5a ). Thus, the mitogenic actions of neuroblastoma-derived NPY on endothelial cells are highly dependent on Y2R.
In line with these results, in SK-N-BE(2) xenografts, Y2R was detected not only in tumor cells, but also in endothelium of tumor vasculature (Figure 4a ). Moreover, Y2R antagonist-treated SK-N-BE(2) xenografts appeared to have lower vascularization, as measured by the number of arteries per cm 2 , although differences did not reach statistical significance (Figure 5b ). However, there were statistically significant differences in mRNA levels of mouse endothelial markers, CD31 and VEGFR2, suggesting antiangiogenic effects of Y2R antagonist (Figure 5b) . Moreover, the treated tumors exhibited high levels of focal fibrosis (Figure 5b) , which is considered a sign of tumor necrosis following ischemia and its subsequent regression. This antiangiogenic effect of Y2R antagonist was further confirmed in SK-N-AS xenografts, in which a significant decrease in the area of CD31-positive vessels was observed (Figure 5c ).
NPY and its Y2R are expressed in human neuroblastomas
To validate our findings in experimental models, we tested the expression of NPY and Y2R in human neuroblastoma samples by immunohistochemistry and real-time RT-PCR. Out of 20 tumor samples derived from neuroblastoma patients at different stages of the disease, 85% stained positively for NPY. The peptide was detected in primary tumors, both differentiating and undifferentiated, as well as in lymph node metastases (Figure 6a ). Positive immunostaining for Y2R was observed in 80% of neuroblastoma cases. As with NPY, Y2R staining was detected in both differentiating tumors and their undifferentiated, aggressive counterparts ( Figure 6a ). Strong Y2R staining was also observed in endothelial cells within the tumor vasculature. The expression of NPY and Y2R in neuroblastoma tissues was also confirmed by real-time RT-PCR. All tissues expressed variable, but very high levels of NPY and Y2R mRNA (Figure 6b ).
Discussion
High expression of NPY and its receptors in neuroblastomas has previously only been considered as a marker of neuronal differentiation (Sheriff et al., 1998; Magni et al., 2000) , with little attention given to the role of NPY signaling in neuroblastoma biology. However, reports correlating elevated NPY plasma levels with poor clinical outcome of the disease (Cohen et al., 1990; Kogner et al., 1994; Dotsch et al., 1998) , as well as emerging evidence on growth-promoting and angiogenic effects of the peptide (Zukowska-Grojec et al., 1998; Hansel et al., 2001; Lee et al., 2003b; Movafagh et al., 2006) , suggest that NPY does have an integral role in the regulation of neuroblastoma growth. Our previous studies indicated that NPY stimulates growth of neuroblastomas by an autocrine mitogenic effect on tumor cells and by its angiogenic activity (Kitlinska et al., 2005) . As both processes are mediated mainly by Y2R, here we assessed this receptor as a potential therapeutic target for the treatment of aggressive neuroblastomas. Our aim was to determine the extent to which the endogenous NPY system is essential for the stimulation of neuroblastoma growth, and, consequently, if blocking its effects by targeting Y2Rs will be sufficient to inhibit neuroblastoma growth in vivo.
Previously, we have found that exogenous NPY stimulates neuroblastoma cell proliferation by p44/42 
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C Lu et al MAPK activation (Kitlinska et al., 2005) . In this study, we showed that blockade of the endogenous NPY/Y2R pathway results in reduced levels of active p44/42 MAPK and marked decreases in the proliferation rate of neuroblastoma cells, as well as induction of Bim-mediated apoptosis. Bim is a member of the Bcl-2 family known to stimulate apoptosis upon growth factor withdrawal (Whitfield et al., 2001; Lei and Davis, 2003; Putcha et al., 2003) . p44/42 MAPK has been shown to phosphorylate BimEL, which promotes its degradation and prevents apoptosis (Ley et al., 2003) . In neuroblastoma cells, p44/42 MAPK-driven regulation of Bim has been implicated in prosurvival activity of brain-derived neurotrophic factor (Li et al., 2007) . Here, we have shown that in SK-N-BE(2) cells, a selective inhibitor of p44/42 MAPK activation, PD098059, not only significantly increases levels of all three forms of Bim, but also converts BimEL to its more stable, non-phosphorylated form. Consequently, in the same cells treated with Y2R antagonist or Y2R siRNA, decreases in p44/42 activation resulted in similar changes in Bim levels and phosphorylation.
Interestingly, the extent to which inhibition of proliferation and apoptosis contribute to the observed growth-inhibitory effects may vary. For example, in SK-N-AS cells, NPY siRNA upregulated Bim and induced apoptosis, while Y2R siRNA caused a decrease in cell proliferation. In Y2R antagonist-treated SK-N-BE(2) cells, both growth-inhibitory processes were observed. Thus, a decrease in p44/42 MAPK activation is a direct consequence of blocking NPY/Y2R pathway, which in turn results in a decrease in proliferation and/or an increase in Bim-mediated apoptosis. The balance between these two processes may depend on the efficiency of inhibition, basal Y2R and NPY levels, and other factors.
In line with this, in neuroblastoma xenografts, treatment with Y2R antagonist resulted in marked reduction of phospho-p44/42 MAPK, but no detectable changes in Bim levels. This may result from the fact that despite a statistically significant increase in apoptosis with Y2R antagonist treatment, overall levels of cell death were relatively low, possibly below the detection level of the western blot. Thus, even though apoptosis seems to contribute to the growth-inhibitory effect of Y2R antagonist in vivo, the marked reduction in cell proliferation appears to be the major consequence of decreased p44/42 MAPK activation and the main mechanism of this phenomenon.
Although the mechanisms of Y2R antagonist actions in vitro and in vivo seemed to be consistent, the magnitude of the effect was strikingly different. The modest effects of Y2R antagonist on neuroblastoma cells in culture translated into highly effective growth inhibition in vivo, suggesting that actions of endogenous NPY are enhanced by factors present in the tumor microenvironment. In addition, in vivo, the antiproliferative effect of Y2R antagonist on neuroblastoma cells is further augmented by its antiangiogenic actions. Our previous results indicated that exogenous NPY enhances vascularization of neuroblastoma xenografts (Kitlinska et al., 2005) . In this study, we showed that endothelial cells within neuroblastoma xenografts and human neuroblastoma vasculature are highly Y2R-positive and that Y2R antagonist decreases basal angiogenesis in neuroblastoma xenografts.
Neuroblastomas are highly vascularized, angiogenesis-dependent tumors, in which the degree of vascularization has been linked to adverse prognosis and a poor outcome of the disease (Meitar et al., 1996) . Combinations of different antiproliferative and antiangiogenic agents have already been tested and proven effective in animal models of the disease and in clinical studies (Ribatti and Ponzoni, 2005; Shusterman and Maris, 2005; Rossler et al., 2008) . Thus, the Y2R antagonist treatment, targeting both formation of blood vessels and cancer cell proliferation, seems to be a promising approach, in line with other currently tested neuroblastoma therapies. Notably, NPY does not seem to be involved in developmental angiogenesis, as both Y2 and NPY knockout mice do not have any known organ defects. This is particularly important as neuroblastoma therapy is applied to children with active angiogenesisdependent developmental processes.
As discussed above, treatment with Y2R antagonist, BIIE0246, significantly inhibited neuroblastoma xenograft growth. Notably, this antagonist is known to be extremely unstable, with an in vivo half-life of only 30 min (Malmstrom, 2001) . As indicated by the enhanced growth-inhibitory effect with combined NPY and Y2R siRNAs, the efficiency of NPY pathway inhibition is an important factor determining the magnitude of the response. Thus, the success of Y2Rtargeted treatment could be increased by developing new, more efficient and stable antagonists. Moreover, the role of other NPY receptors also expressed in some neuroblastoma cells (Kitlinska et al., 2005) and the effect of therapies targeting multiple NPY receptors remain to be investigated.
The clinical relevance of our experimental findings is supported by the expression of NPY and its Y2R in human neuroblastoma tissues shown here and previously reported by others (Korner et al., 2004) . The fact that expression of both NPY and Y2R was detected in all tested neuroblastoma cell lines and in a high percent of neuroblastoma tissues proves their value as universal therapeutic targets. This is in contrast to some other molecules implicated in neuroblastoma, such as ALK. ALK is a recently discovered, very promising target in neuroblastoma therapy. However, the inhibitors of this molecule affect only a subset of tumors with ALK mutations (Chen et al., 2008; George et al., 2008; Mosse et al., 2008) . For example, the growth of SK-N-AS cells, which was significantly inhibited by Y2R antagonist in vitro and in vivo, is not affected by ALK inhibitors (Mosse et al., 2008) . Thus, owing to the universal nature of the NPY growth-promoting effects, targeting its Y2R may be a supplementary treatment to those more selective therapies.
Taken together, we have shown for the first time that blocking Y2R is sufficient to inhibit neuroblastoma growth in vivo. The main mechanisms of this effect include inhibition of tumor cell proliferation with some contribution of apoptosis and impairment of angiogenesis. The efficiency of this treatment can be further enhanced by designing more potent Y2R antagonists. Therefore, NPY and its Y2R are promising new targets in neuroblastoma therapy.
Materials and methods
Materials NPY was purchased from Bachem (San Carlos, CA, USA), Y2R antagonist, BIIE0246, from Tocris (Ellisville, MO, USA) and MAPK kinase 1 inhibitor, PD089059, from Sigma (St Louis, MO, USA).
Cell culture
Human neuroblastoma cells, SK-N-BE(2), SK-N-AS, SK-N-SH and SHSY5Y, were obtained from ATCC (Manassas, VA, USA), and SMS-KAN, SMS-KANR, CHLA-15 and CHLA-20 cells were obtained from Dr Patrick Reynolds (Children's Hospital of Los Angeles, Los Angeles, CA, USA). HMVECs were purchased from Lonza (Basel, Switzerland). All cell lines were cultured as per the manufacturer's instruction. To create hypoxic conditions, HMVEC cells were cultured in a hypoxic chamber containing 0.1% oxygen for 24 h.
Cell viability and apoptosis assays
The cells cultured in 96-well plates were put into 1% fetal bovine serum (FBS) media and 24 h later treated with the Y2R antagonist. After 24 h, the caspase 3/7 activity was measured using Apo-ONE Homogenous Caspase 3/7 reagent (Promega, Madison, WI, USA), whereas the number of viable cells was measured 48 h after treatment using CellTiter 96AQueous One Solution Cell Proliferation Assay (Promega).
Cell proliferation SK-N-BE(2) cells cultured in 1% FBS for 24 h were treated with Y2R antagonist at desired concentrations. At 4 h after treatment, 10 mM BrdU was added to the media. After 8 h, the cells were trypsinized and stained with anti-BrdU antibody (Ab) using BrdU Flow Kit (BD Biosciences, San Diego, CA, USA). Flow cytometric analysis was performed on FACSort (Becton Dickinson, Franklin Lakes, NJ, USA) and data were analyzed using CellQuest and ModFit LT softwares (Verity Software House Inc., Topsham, ME, USA). The siRNAtreated cells were incubated for 1 h with 5 mM EdU, fixed and stained using Click-it EdU Proliferation Kit (Invitrogen, Carlsbad, CA, USA). The percent of stained cells was evaluated by fluorescence microscopy.
Real-time RT-PCR RNA from culture cells was isolated using High Pure RNA Isolation Kit (Roche Applied Science, Indianapolis, IN, USA) and from tissues using TRI reagent (Sigma). cDNA was synthesized using iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA) and amplified using ICycler iQ Detection System (Bio-Rad Laboratories). The PCR reactions were carried out using TaqMan Universal PCR Master Mix and pre-designed primers and fluorescein-labeled probes (Applied Biosystems, Foster City, CA, USA). The results were calculated by the comparative C T method using b-actin as an endogenous reference gene. siRNA transfection NB cells were transfected with 30 nM pre-designed siRNAs for NPY, Y2R or negative control (Applied Biosystems) using Trans IT-TKO reagent (Mirus, Madison, WI, USA), and 24 h later, media were changed to fresh 10 or 1% FBS media. The efficiency of siRNA inhibition was tested by real-time RT-PCR, western blot (Y2R) or Neuropeptide Y Enzyme Immunoassay (Bachem), and cell viability, apoptosis and proliferation were assessed as above.
Western blot SK-N-BE(2) cells cultured in 1 or 5% FBS media for 24 h were stimulated with Y2R antagonist (10 À8 -10 À6 M) or MAPK kinase 1 inhibitor, PD089059 (5 Â 10 À5 M), and harvested after 6, 12 and 24 h. The siRNA transfected cells at the desired time points and tissue samples were lysed as described previously (Kitlinska et al., 2005) . The proteins of interest were detected using the following antibodies: phospho-p44/42 MAPK E10 mouse monoclonal Ab, rabbit polyclonal antibodies against p44/42 MAPK, Bim, phospho-Bad (Ser155), phospho-Akt (Ser473), rabbit monoclonal Ab against Bcl-xl (Cell Signaling Technology, Inc., Beverly, MA, USA), goat polyclonal anti-Npy2r Ab (Biosource, Camarillo, CA, USA) and anti-b-actin mouse monoclonal Ab (Sigma). Densitometry was performed using NIH Scion Image software (Scion Corp., Frederick, MD, USA). Each immunoblot was repeated at least three times and representative results are shown in figures.
Nude mice xenograft model
Nude mice (7-10 weeks old; Taconic, Hudson, NY, USA) were subcutaneously injected into their right flank with 5 Â 10 6 of SK-N-BE(2) or SK-N-AS cells suspended in 0.1 ml of Matrigel (BD Biosciences). One day or 10-14 days after tumor cell inoculation, the daily treatment with Y2R antagonist administered as local injection (approximately 1 cm from the tumor) of 100 ml of 10 À6 M solution in saline or saline alone was started. Tumor size was measured periodically and volume calculated by the formula: 0.44 Â length Â width 2 (Wassberg, 1999) . At the end of the experiment, mice were euthanized and tumors were harvested, measured and weighed. The animal protocol was approved by the Georgetown University Animal Care and Use Committee.
Human neuroblastoma tissues
Samples of 20 human neuroblastoma tumors (matched formalin-fixed tissues and RNA samples) from different stages of the disease were received from Children's Oncology Group.
Immunohistochemistry and tumor vascularization
Immunostaining was performed using the following antibodies: rabbit polyclonal anti-NPY and anti-Y2R Ab provided by AstraZeneca (Mo¨lndal, Sweden) (Naveilhan et al., 1999; Uddman et al., 2002; Ekstrand et al., 2003; Jonsson-Rylander et al., 2003) , Ki67 mouse monoclonal Ab (Oncogene Research Products, Boston, MA, USA) and CD31 rat monoclonal Ab (BD Pharmingen, San Jose, CA, USA). TUNEL assay was performed using In Situ Cell Detection Kit (Roche Diagnostic, Indianapolis, IN, USA). The proliferation and apoptosis rates and tissue vascularization were calculated as an area of positive staining using NIH Scion Image software (Scion Corp.) and NIH Image J. Vascularization of SK-N-BE(2) xenografts was measured as the number of arteries per cm 2 , based on hematoxylin-and eosin-stained slides, using Automated Cellular Imaging System II (Clarient Inc., San Juan Capistrano, CA, USA).
HMVEC proliferation
SK-N-BE(2) cells were grown in HMVEC culture media (Lonza) with 0.25% FBS for 24 h. Then, the medium was collected and used to stimulate HMVEC cell proliferation at dilution 0.5 Â . HMVECs at passages 4-8 were plated onto 96well plates, growth arrested in serum-free media for 24 h and then treated for 24 h with NPY-(10 À8 M) or SK-N-BE(2)conditioned media, with or without Y2R antagonist (10 À6 M) in media supplemented with 0.25% FBS. The proliferation was measured using [ 3 H]thymidine as described previously (Kitlinska et al., 2005) .
Statistical analysis
Statistical analysis was performed using SigmaStat software. One-way repeated measure analysis of variance with post hoc ttest (Po0.05) using Dunnett's method was used for data analysis. Data are presented as mean±standard errors. The comparison of tumor growth in the in vivo experiments on SK-N-BE(2) cells was performed using Wilcoxon's rank-sum test to compare the differences of increases in tumor volumes from baseline. For the analysis of the SK-N-AS xenografts, the log-transformed tumor volumes were compared using linear mixed models to account for the repeated measures of each animal.
